Absci

Absci is a clinical-stage biopharmaceutical company using generative artificial intelligence to discover biology and create differentiated biologic medicines. Its mission is to develop better biologics for patients faster, addressing the historically lengthy, high-failure-rate process of biologics drug discovery. The company combines computational AI with wet-lab experimentation in iterative cycles to generate data, train models, design biologics from scratch, and optimize promising leads. Absci says these cycles can run in six weeks.

Its integrated AI Drug Creation Platform supports internal drug development and collaborations with pharmaceutical, technology, and academic partners. The company also applies AI-enabled reverse immunology to identify antibodies produced by super-immune responders, creating antibody-target pairs for further optimization and development. Absci’s pipeline includes ABS-201, a novel antibody targeting the prolactin receptor. Designed to stimulate hair follicle regeneration and promote durable hair regrowth, ABS-201 is being evaluated in the HEADLINE trial, for which Absci has announced positive interim Phase 1 data.